Patents by Inventor Kent Jørgensen

Kent Jørgensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Liposomes for drug delivery and methods for preparation thereof
    Patent number: 11173178
    Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: November 16, 2021
    Assignee: LiPlasome Pharma ApS
    Inventors: Anders Falk Vikbjerg, Sune Allan Petersen, Fredrik Melander, Jonas Rosager Henriksen, Kent Jørgensen
  • LIPOSOMES FOR DRUG DELIVERY AND METHODS FOR PREPARATION THEREOF
    Publication number: 20200171080
    Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.
    Type: Application
    Filed: February 10, 2020
    Publication date: June 4, 2020
    Inventors: Anders Falk VIKBJERG, Sune Allan PETERSEN, Fredrik MELANDER, Jonas Rosager HENRIKSEN, Kent JØRGENSEN
  • LIPOSOMES FOR DRUG DELIVERY AND METHODS FOR PREPARATION THEREOF
    Publication number: 20120009243
    Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.
    Type: Application
    Filed: May 25, 2009
    Publication date: January 12, 2012
    Applicant: LIPLASOME PHARMA APS
    Inventors: Anders Falk Vikbjerg, Sune Allan Petersen, Fredrik Melander, Jonas Rosager Henriksen, Kent Jørgensen
  • Lipid-based systems for targeting diagnostic agents
    Patent number: 7368254
    Abstract: The invention relates to targeting of diagnostic agents by use of lipid-based compositions. The invention is useful in the diagnosis of various disorders which are associated with or resulting from increased levels of extracellular PLA2 activity in the diseased tissue, e.g. cancer, infectious, and inflammatory conditions.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: May 6, 2008
    Assignee: Liplasome Pharma A/S
    Inventors: Kent Jørgensen, Jesper Davidsen, Charlotte Vermehren, Sven Frøkjær, Ole G. Mouritsen
  • Lipid-based drug delivery systems against parasitic infections
    Patent number: 7166297
    Abstract: The present invention is directed to a lipid-based delivery system for administration of an active drug substance selected from lysolipid derivatives which are particularly useful in the treatment or detection of parasitic infections, especially parasitic infections which cause an elevated PLA2 level in the infected mammal. Preferred parasitic infections are infections wherein the life cycle of the parasite involves the liver and/or spleen of the infected organism.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: January 23, 2007
    Assignee: LiPlasome Pharma A/S
    Inventors: Kent Jørgensen, Jesper Davidsen, Charlotte Vermehren, Sven Frøkjer, Ole G. Mouritsen